TY - JOUR
T1 - Predictions of time to HIV viral rebound following ART suspension that incorporate personal biomarkers
AU - Conway, Jessica M.
AU - Perelson, Alan S.
AU - Li, Jonathan Z.
N1 - Funding Information:
JMC acknowledges the support of the National Science Foundation (https://nsf.gov) under Grant No. DMS-1714654. ASP acknowledges the support of National Institutes of Health (https://www.nih.gov/) Grants R01-AI028433, R01-OD011095, and P01-AI131365; his work was performed under the auspices of US Department of Energy Contract 89233218CNA000001. JZL acknowledges support by National Institutes of Health (https://www.nih.gov/) Grants AI114448, UM1 AI068636 (AIDS Clinical Trials Group), and a subcontract from UM1 AI068636 to the Harvard Virology Support Laboratory. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank Timothy Charles Reluga for valuable technical discussions and insights. We thank the participants, staff, and principal investigators of the ACTG studies A371 (Paul Volberding, Elizabeth Connick), A5024 (J. Michael Kilby, Ronald Mitsuyasu), A5068 (Jeffrey Jacobson, Ian Frank, Michael Saag, Joseph Eron), A5170 (Daniel Skiest, David Margolis, Diane Havlir), and A5197 (Robert Schooley, Michael Lederman, Diane Havlir). We also thank the efforts of the ACTG NWCS 371 study team.
Publisher Copyright:
© 2019, Public Library of Science. All rights reserved.
PY - 2019/7
Y1 - 2019/7
N2 - Antiretroviral therapy (ART) effectively controls HIV infection, suppressing HIV viral loads. Suspension of therapy is followed by rebound of viral loads to high, pre-therapy levels. However, there is significant heterogeneity in speed of rebound, with some rebounds occurring within days, weeks, or sometimes years. We present a stochastic mathematical model to gain insight into these post-treatment dynamics, specifically characterizing the dynamics of short term viral rebounds (≤ 60 days). Li et al. (2016) report that the size of the expressed HIV reservoir, i.e., cell-associated HIV RNA levels, and drug regimen correlate with the time between ART suspension and viral rebound to detectable levels. We incorporate this information and viral rebound times to parametrize our model. We then investigate insights offered by our model into the underlying dynamics of the latent reservoir. In particular, we refine previous estimates of viral recrudescence after ART interruption by accounting for heterogeneity in infection rebound dynamics, and determine a recrudescence rate of once every 2-4 days. Our parametrized model can be used to aid in design of clinical trials to study viral dynamics following analytic treatment interruption. We show how to derive informative personalized testing frequencies from our model and offer a proof-of-concept example. Our results represent first steps towards a model that can make predictions on a person living with HIV (PLWH)’s rebound time distribution based on biomarkers, and help identify PLWH with long viral rebound delays.
AB - Antiretroviral therapy (ART) effectively controls HIV infection, suppressing HIV viral loads. Suspension of therapy is followed by rebound of viral loads to high, pre-therapy levels. However, there is significant heterogeneity in speed of rebound, with some rebounds occurring within days, weeks, or sometimes years. We present a stochastic mathematical model to gain insight into these post-treatment dynamics, specifically characterizing the dynamics of short term viral rebounds (≤ 60 days). Li et al. (2016) report that the size of the expressed HIV reservoir, i.e., cell-associated HIV RNA levels, and drug regimen correlate with the time between ART suspension and viral rebound to detectable levels. We incorporate this information and viral rebound times to parametrize our model. We then investigate insights offered by our model into the underlying dynamics of the latent reservoir. In particular, we refine previous estimates of viral recrudescence after ART interruption by accounting for heterogeneity in infection rebound dynamics, and determine a recrudescence rate of once every 2-4 days. Our parametrized model can be used to aid in design of clinical trials to study viral dynamics following analytic treatment interruption. We show how to derive informative personalized testing frequencies from our model and offer a proof-of-concept example. Our results represent first steps towards a model that can make predictions on a person living with HIV (PLWH)’s rebound time distribution based on biomarkers, and help identify PLWH with long viral rebound delays.
UR - http://www.scopus.com/inward/record.url?scp=85071070412&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071070412&partnerID=8YFLogxK
U2 - 10.1371/journal.pcbi.1007229
DO - 10.1371/journal.pcbi.1007229
M3 - Article
C2 - 31339888
AN - SCOPUS:85071070412
SN - 1553-734X
VL - 15
JO - PLoS computational biology
JF - PLoS computational biology
IS - 7
M1 - e1007229
ER -